Skip to content

AbbVie

Public companyUSfounded 20132 fields

Website

Where it works

Technology
Longevity biotechPartnered with Calico on aging drug research for over a decade before ending the alliance in 2025.
NanotechnologyBought Capstan's in vivo tLNP CAR-T program for $2.1 billion in cash.

Events

DateEvent
Nov 12, 2025AbbVie ends its decade-long partnership with Calicostatnews.com· Deal· Longevity biotech
About
Source
statnews.com (press, added by seed)
First seen
Sep 25, 2026
Last seen
Sep 25, 2026
DateChange
Sep 25, 2026AbbVieCompany in Nanotechnology: Joined a field, Bought Capstan's in vivo tLNP CAR-T program for $2.1 billion in cash.
Sep 25, 2026AbbVieCompany in Longevity biotech: Joined a field, Partnered with Calico on aging drug research for over a decade before ending the alliance in 2025.
Sep 25, 2026AbbVieCompany: Added

Frontier tech by email

Tuesdays, only in weeks with new milestones, rounds or stage changes in the fields tracked here.

Double opt-in. Unsubscribe any time.